bioRxivImmunology
Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia
J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, A. Cesano, A. G. Pockley, P. J. Valk, B. Lowenberg, M. Bornhauser, S. K. Tasian, M. P. Rettig, J. K. Davidson-Moncada, J. F. DiPersio, S. Rutella
Abstract
This study dissected the complexity of the immune architecture of acute myeloid leukemia (AML) at high resolution and assessed its influence on therapeutic response. Using 387 primary bone marrow samples from three discovery cohorts of children and adults with AML, we defined immune-infiltrated and immune-depleted disease subtypes and unraveled critical differences in immune gene expression across age groups and disease stages. Importantly, interferon (IFN)-{gamma}-related mRNA profiles were predictive for both chemotherapy resistance and response of primary refractory/relapsed AML to flotetuzumab immunotherapy. Our compendium of microenvironmental gene and protein profiles sheds novel insights into the immuno-biology of AML and will inform the delivery of personalized immunotherapies to IFN-{gamma}-dominant AML subtypes.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A 3-genes interferon signature predicts sustained complete remission in pediatric AML patients
Shimaa Sherif, Aesha I. Ali, … Sara Deola·bioRxiv·Jul 17, 2025
- Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy
H. A. Abbas, D. Hao, … A. Futreal·bioRxiv·Sep 3, 2020
- TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia
C. Lai, J. Vadakekolathu, … S. Rutella·bioRxiv·Feb 28, 2020
- Dynamic regulation of hierarchical heterogeneity in Acute Myeloid Leukemia serves as a tumor immunoevasion mechanism
C. Pospori, W. Grey, … C. L. Lo Celso·bioRxiv·Dec 21, 2020
- A combined program of induced stemness and differentiation in response to interferon gamma drives acute myeloid leukaemia growth
Constandina Pospori, Alessandro Donada, … Cristina Lo Celso·bioRxiv·Sep 10, 2026
- Immunosuppression and Outcomes in Acute Myeloid Leukemia
F. Ferraro, C. Miller, … T. J. Ley·bioRxiv·Sep 3, 2021